Zoetis Inc. — Form 10-Q Summary
Business context and reporting period
Zoetis is a global animal-health medicines and vaccines company serving livestock and companion-animal markets. This unaudited quarterly report covers the three and nine months ended September 28, 2014; comparisons are with periods ended September 29, 2013. The 2013 nine-month comparison includes both pre- and post-separation results, including certain allocations from Pfizer, and may not be fully comparable with Zoetis as a standalone company.
Financial performance
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $1.210 billion | $1.103 billion | $3.465 billion | $3.307 billion |
| Net income attributable to Zoetis | $166 million | $131 million | $457 million | $399 million |
| Diluted EPS | $0.33 | $0.26 | $0.91 | $0.80 |
| Adjusted net income (non-GAAP) | $207 million | $172 million | $587 million | $529 million |
- Revenue increased 10% in Q3 and 5% in the first nine months. Operational revenue growth was 10% and 6%, respectively; nine-month growth comprised 4% volume and 2% price, partly offset by a 1% unfavorable foreign-exchange impact.
- Q3 gross margin was approximately 64.1% of revenue, versus 65.1% a year earlier; nine-month gross margin was approximately 64.6%, versus 63.6%. Cost of sales rose 13% in Q3, reflecting volume, manufacturing and supply costs, and higher inventory obsolescence and scrap charges.
- Income before taxes was $238 million in Q3 and $665 million for nine months. Net income attributable to Zoetis was 14% and 13% of revenue, respectively, compared with 12% in each prior-year period. Effective tax rates were 29.8% in Q3 and 30.7% for nine months, up from 29.2% and 29.3%.
- Operating cash flow was $239 million for nine months, down from $383 million. Capital expenditures were $129 million; investing cash use was $137 million. Cash declined $12 million to $598 million.
- At September 28, cash was $598 million, working capital was $2.355 billion, and the current ratio was 3.36:1. Long-term debt was $3.642 billion and short-term borrowings were $10 million. The $1.0 billion revolving credit facility was undrawn, and Zoetis reported compliance with its financial covenants.
Material changes and management commentary
- Q3 revenue growth was broad-based across regions and was led by the U.S.; livestock revenue grew 13% operationally and companion-animal revenue grew 5%. Apoquel launches supported companion-animal growth. For nine months, livestock revenue grew 8% operationally and companion-animal revenue 3%.
- All four geographic segments reported Q3 revenue growth. Nine-month foreign-exchange pressure was most pronounced in CLAR and APAC; CLAR operational growth was 12% despite an 8% currency impact, while APAC operational growth was 5%.
- Management cited higher global manufacturing and supply spending and continued standalone-company build-out costs. Nine-month stand-up costs were $106 million, versus $152 million in the comparable 2013 period. The company expected total 2014 nonrecurring costs, including specified stand-up and other items, of approximately $180–$195 million.
- Operating cash flow declined primarily due to the timing of ordinary-course receipts and payments, including settlement of Pfizer payables, and lower accrued liabilities. Inventory increased as Zoetis built safety stock for production transfers, ERP implementation, and demand.
Guidance, risks and unusual items
- 2014 guidance: revenue of $4.700–$4.750 billion; adjusted diluted EPS of $1.50–$1.54; and reported diluted EPS of $1.16–$1.20. Adjusted guidance excludes purchase-accounting adjustments, acquisition-related costs and certain significant items. Guidance reflects then-current exchange rates and remains subject to stated risks.
- In September, USDA granted a conditional license for Zoetis’s PEDv vaccine; supply began that month, with further studies required for full U.S. licensure. Management said PEDv was not expected to have a significant impact on 2014 revenue, while noting the outbreak’s continued spread.
- A July recall and commercial settlement involving specific poultry-vaccine lots in Mexico followed a possible third-party storage issue; the filing says no manufacturing quality or efficacy issue was identified. Zoetis recorded a $13 million charge, partly offset by a $1 million insurance recovery, and did not expect significant additional charges.
- Other notable items included a $6 million impairment of acquired in-process R&D after termination of a dog-product development program, foreign-currency losses, and a pension settlement charge related to a previously sold manufacturing facility.
- Key risks include restrictions on livestock antibacterials, animal-disease outbreaks, weather and resource constraints, foreign-exchange movements and currency controls (including Venezuela), competition, manufacturing disruptions or recalls, litigation, and implementation risks associated with the multi-year ERP migration. Management stated disclosure controls were effective; no material quarterly change in internal control was reported.
- Legal matters include product-related claims, patent litigation, and environmental proceedings. Management stated it could not estimate reasonably possible losses in excess of accrued amounts; it did not believe the matters would materially adversely affect financial position, while acknowledging potential effects on results or cash flows.
Important facts for investors to verify
- Whether revenue and earnings growth persist after adjusting for currency, price, volume, and the limited comparability of the 2013 standalone transition period.
- Progress against 2014 revenue and EPS guidance, including the level and composition of excluded items and remaining separation-related costs.
- Whether operating cash flow recovers and inventory levels normalize after safety-stock accumulation and Pfizer-related payment timing.
- Debt-service capacity, covenant headroom, and the impact of fixed-rate debt maturities beginning in 2016.
- Developments in PEDv vaccine licensing and the Mexico vaccine recall, as well as potential effects of antibacterial restrictions, currency controls, litigation, and ERP implementation.